Sarwat Tahsin Khan

Sarwat Tahsin Khan

Auto-generated profile, based on publicly available information

Sarwat Tahsin Khan

Cancer Therapeutic Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JHJonathan J. Hodgins
Jonathan J. Hodgins
SKSarwat T. Khan
Sarwat T. Khan
MPMaria M. Park
Maria M. Park
RARebecca C. Auer
Rebecca C. Auer
MAMichele Ardolino
Michele Ardolino
Natural killer (NK) cells are innate cytotoxic lymphocytes involved in the surveillance and elimination of cancer. As we have learned more and more about the mechanisms NK cells employ to recognize and eliminate tumor cells, and how, in turn, cancer evades NK cell responses, we have gained a clear appreciation that NK cells can be harnessed in cancer immunotherapy. Here, we review the evidence for NK cells’ critical role in combating transformed and malignant cells, and how cancer immunotherapies potentiate NK cell responses for therapeutic purposes. We highlight cutting-edge immunotherapeutic strategies in preclinical and clinical development such as adoptive NK cell transfer, chimeric antigen receptor–expressing NK cells (CAR-NKs), bispecific and trispecific killer cell engagers (BiKEs and TriKEs), checkpoint blockade, and oncolytic virotherapy. Further, we describe the challenges that NK cells face (e.g., postsurgical dysfunction) that must be overcome by these therapeutic modalities to achieve cancer clearance.

Verified
Journal Article
Open access
PDF file
LALeonard Angka
Leonard Angka
SKSarwat T. Khan
Sarwat T. Khan
MKMarisa K. Kilgour
Marisa K. Kilgour
RXRebecca Xu
Rebecca Xu
MKMichael Kennedy
Michael Kennedy
RARebecca C. Auer
Rebecca C. Auer
The physiological changes that occur immediately following cancer surgeries initiate a chain of events that ultimately result in a short pro-, followed by a prolonged anti-, inflammatory period. Natural Killer (NK) cells are severely affected during this period in the recovering cancer patient. NK cells play a crucial role in anti-tumour immunity because of their innate ability to differentiate between malignant versus normal cells. Therefore, an opportunity arises in the aftermath of cancer surgery for residual cancer cells, including distant metastases, to gain a foothold in the absence of NK cell surveillance. Here, we describe the post-operative environment and how the release of sympathetic stress-related factors (e.g., cortisol, prostaglandins, catecholamines), anti-inflammatory cytokines (e.g., IL-6, TGF-β), and myeloid derived suppressor cells, mediate NK cell dysfunction. A snapshot of current and recently completed clinical trials specifically addressing NK cell dysfunction post-surgery is also discussed. In collecting and summarizing results from these different aspects of the surgical stress response, a comprehensive view of the NK cell suppressive effects of surgery is presented. Peri-operative therapies to mitigate NK cell suppression in the post-operative period could improve curative outcomes following cancer surgery.

8 June 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
SKSarwat T Khan
Sarwat T Khan
JMJoshua Montroy
Joshua Montroy
NFNicole Forbes
Nicole Forbes
DBDonald Bastin
Donald Bastin
MKMichael Kennedy
Michael Kennedy
RARebecca C Auer
Rebecca C Auer
Introduction: Autologous cancer cell vaccines are promising personalised immunotherapeutic options for solid and haematological malignancies that uses the patient’s own cells to arm an immune response. Evidence suggests that among patients receiving these vaccines, those who mount an immune response against their own tumour cells have better prognosis, and a myriad of preclinical studies have demonstrated the same. Recently, two autologous cell vaccines Vigil and OncoVAX have made it to phase III clinical trials. Here, we outline a protocol to be used for two separate systematic reviews using a parallel approach for inclusion criteria, data extraction and analysis for autologous cell vaccines in (1) solid and (2) haematological malignancies. We aim to review evidence from controlled and uncontrolled interventional studies of autologous cell vaccines administered to patients with cancer to determine their historical efficacy (with or without associated adjuvants or modifications) with clinical response rates and safety outcomes being of particular importance. Methods and analysis: We will search MEDLINE (OVID interface, including In-Process and Epub Ahead of Print), Embase (OVID interface) and the Cochrane Central Register of Controlled Trials (Wiley interface) for articles published from 1947 until 30 July 2018 (date search was performed). Studies will be screened first by title and abstract, then by full-text in duplicate. Interventional trials that report the use of an autologous cell vaccine to patients with cancer of any age will be included. The primary outcomes of interest in this review are clinical response (complete or overall/objective response) and safety outcomes (adverse events). Secondary outcomes include immune response, disease-free survival and overall survival. The risk of bias within studies will be assessed using the appropriate Cochrane Risk of Bias tool. If appropriate, a random effects meta-analysis will be performed to synthesise the data and report summary estimates of effect. Statistical heterogeneity will be assessed using the I 2 statistic. Ethics and dissemination: Ethics approval is not required for this systematic review protocol as the review will solely use published literature. Results will be submitted to peer-reviewed journals for publication and presented to relevant stakeholders and scientific meetings. PROSPERO registration number: CRD42019140187.

20 December 2017 in Immunology
Verified
Journal Article
Open access
PDF file
SKSarwat Tahsin Khan
Sarwat Tahsin Khan
WKWinston Karges
Winston Karges
CCCurtis L. Cooper
Curtis L. Cooper
ACAngela M Crawley
Angela M Crawley
Summary: Clearance of hepatitis C virus (HCV) is dependent on an effective virus‐specific CD8+ T‐cell response, which is dysfunctional in chronic HCV infection. Dysfunction in bulk or non‐HCV‐specific CD8+ T‐cells in HCV infection has also been observed. This may contribute to observed reductions in immunity to other diseases (e.g. cancer, viral co‐infections) in HCV‐infected individuals. Evidence suggests that the HCV core protein (found in blood as free protein) may contribute to this impairment. To determine if HCV core contributes to the impairment of effector functions and survival potential of CD8+ T‐cells, isolated human CD8+ T‐cells from healthy donors were pre‐incubated with recombinant HCV core protein for 72 hr and then stimulated in vitro to evaluate proliferation, survival potential and effector functions. Pre‐incubation of stimulated CD8+ T‐cells with HCV core significantly reduced their proliferation. Perforin production and degranulation were also decreased, but interferon‐γ production was unchanged. Additionally, when CD8+ T‐cells were treated with serum from HCV+ individuals, they produced less perforin than cells treated with healthy serum. Up‐regulation of anti‐apoptotic Bcl‐2 was slightly lower in cells treated with HCV core, but signal transducer and activator of transcription 5 (STAT5) activation was increased, suggesting dysregulation downstream of STAT activation. Our study reveals that HCV core reduces the activity and target lysis‐associated functions of CD8+ T‐cells. This may contribute to the generalized impairment of CD8+ T‐cells observed in HCV infection. These findings provide insight for the design of novel counteractive immune‐mediated strategies including the design of effective therapeutic vaccines for use in HCV+ individuals.

26 April 2017 in Clinical & Investigative Medicine
Verified
Journal Article
Closed access
PDF file
SKSarwat T Khan
Sarwat T Khan
MMMichaeline McGuinty
Michaeline McGuinty
DCDaniel J Corsi
Daniel J Corsi
CCCurtis L Cooper
Curtis L Cooper
Purpose: Monitoring of hepatitis C virus (HCV) treatment response is performed by serial HCV RNA measurements; however, this may not be useful for predicting treatment success or failure with oral direct-acting antiviral agent (DAA) therapies. Liver enzyme levels, which are elevated in chronic HCV and tend to decline on therapy, may serve as a more logistically and economically feasible alternative for monitoring treatment response. Source: The Ottawa Hospital Viral Hepatitis Clinic patients (n=219), receiving interferon-free oral DAA treatments, were assessed for liver enzymes and HCV RNA levels at baseline, week 4 and ≥12 weeks post-treatment. Suppression cut points used for this analysis were ALT ≥ 40U L-1 and AST ≥ 30U L-1. The primary outcome was week 12 sustained virologic response (SVR). By our analysis, all indicators had strong PPV (>90%) but limited NPV (<25%). Principal findings: Along with week 4 HCV RNA, AST . 30U L-1 and AST:ALT ratio at week 4 were associated with SVR in univariate analysis with similar PPV and NPV to HCV RNA. ALT was not predictive of DAA outcome. In multivariate models, adjusting for cirrhosis and genotype, baseline AST:ALT ratio<0.9 (but none of the week 4 indicators) was significantly associated with SVR. Conclusion: Our analysis suggests that enzyme levels (particularly AST and AST:ALT ratio) provide a viable alternative to HCV RNA, with robust predictive value in determining treatment success of DAA therapies.